Catalog No.: PC-72258Not For Human Use, Lab Use Only.
RG7834 (RG-7834, RO7020322) is a potent, specific, orally bioavailable small molecule inhibitor of HBV gene expression, reduces HBV total mRNA levels with EC50 of 5.87 nM.
RG7834 (RG-7834, RO7020322) is a potent, specific, orally bioavailable small molecule inhibitor of HBV gene expression, reduces HBV total mRNA levels with EC50 of 5.87 nM.
RG7834 is highly selective for HBV and unlike current therapy inhibits the expression of viral proteins by specifically reducing HBV mRNAs.
RG7834 inhibited HBV genotypes with similar activity, reducing HBV DNA levels with EC50 of 2.2-6.0 nM, in primary human hepatocytes (PHH) infected with clinical isolates representing the most prevalent HBV genotypes A, B, C, and D.
G7834 does not interfere with the functions or expression levels of major transcription factors in hepatocytes.
RG7834 reduced HBsAg levels and other viral markers in HBV-infected human liver chimeric uPA-SCID mice.
Combination treatment with RG7834 and entecavir or interferon induced a balanced and profound reduction of both viremia and HBsAg levels.
